---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Expected outcomes of therapy"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Expected outcomes of therapy. Topics: Sponsor statements of the intended outcome; Expected outcome of ARCHER II and its uncertainty; Phase 2 basis: primary lesion-growth endpoint not met and prespecified visual acuity analyses; Number needed to treat to avoid confirmed vision loss (prespecified secondary analysis, nominal p values); 1 further topic. 5 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Sponsor statements of the intended outcome

> “It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-preserving therapy for GA.”
> “Vonaprument involves a differentiated neuroprotective approach designed to protect photoreceptor cells and retinal function by blocking C1q and the entire classical pathway, while allowing for normal immune activity of the lectin and alternative complement pathways.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “Assuming success in the ARCHER II trial, ANX007 has the potential to be the first GA therapy approved to protect vision.”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

> “Vision protection is what matters to patients, physicians and payers.”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-2.2.2.7-2"></a>

### Expected outcome of ARCHER II and its uncertainty

> “ARCHER II is designed to demonstrate clinically meaningful vision protection at Months 15 and 24. Given the linear progression of vision loss in GA, we believe longer treatment provides greater potential for sustained treatment benefit and increased separation between vonaprument treatment and sham over time.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

> “Under the dual primary endpoint design, ARCHER II may achieve statistical success at either the Month 15 or Month 24 timepoint.”
> “However, there is no assurance that either timepoint will show a statistically significant treatment effect”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.2.2.7-3"></a>

### Phase 2 basis: primary lesion-growth endpoint not met and prespecified visual acuity analyses

> “The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance.”
> “A 6.2% reduction in lesion growth was observed in monthly treatment group (p=0.526), a 1.3% reduction was observed in the every-other-month treatment group (p-value=0.896) and a 3.7% reduction was observed in the pooled patient population (p-value=0.673).”
> “The study included multiple pre-specified visual function measures to assess the effects of ANX007 on vision:”
> “Over the 12-month treatment period, patients in the ANX007 monthly treatment group showed a 72% reduction in risk of >15-letter vision loss (n=89, p=0.006) and patients in the ANX007 every-other-month treatment group showed a 48% reduction in risk of >15-letter vision loss (n=92, p=0.064).”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-2.2.2.7-4"></a>

### Number needed to treat to avoid confirmed vision loss (prespecified secondary analysis, nominal p values)

> “A Prespecified Secondary Analysis”
> “Nominal p-value from a Chi-square test in ITT population”
> “For every 7 patients treated with ANX007 monthly, 1 additional patient would be spared clinically significant vision loss”
> “Number Needed to Treat EM To Avoid ≥10 LL = 10”
> “Number Needed to Treat EM To Avoid ≥20 LL = 8”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

<a id="topic-2.2.2.7-5"></a>

### Persistence of effect after treatment cessation

> “While benefit was maintained after treatment cessation the rate of BCVA≥15 LL increased to parallel that of sham (>1.6% per month)”
> “Consistent with true on-treatment drug effect and disease-modifying mechanism of action”

Source: [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
